284 related articles for article (PubMed ID: 15984537)
1. [Tumor markers in malignant lymphoma].
Kato H; Ogura M
Gan To Kagaku Ryoho; 2005 Jun; 32(6):883-92. PubMed ID: 15984537
[TBL] [Abstract][Full Text] [Related]
2. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
[TBL] [Abstract][Full Text] [Related]
3. [Clinical significance of serum soluble interleukin-2 receptor level in patients with non-Hodgkin's lymphoma].
Shimomura Y; Tsurumi H; Sawada M; Yamada T; Hara T; Fukuno K; Goto H; Moriwaki H
Rinsho Ketsueki; 1999 Aug; 40(8):639-45. PubMed ID: 10496038
[TBL] [Abstract][Full Text] [Related]
4. [Clinically relevant prognostic factors in malignant lymphoma].
Engelhard M; Löffler M
Internist (Berl); 1993 Feb; 34(2):127-31. PubMed ID: 8454425
[No Abstract] [Full Text] [Related]
5. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
Albitar M; Vose JM; Johnson MM; Do KA; Day A; Jilani I; Kantarjian H; Keating M; O'Brien SM; Verstovsek S; Armitage JO; Giles FJ
Leuk Res; 2007 Feb; 31(2):139-45. PubMed ID: 16545870
[TBL] [Abstract][Full Text] [Related]
6. [Tumor markers in malignant lymphoma].
Banno S; Ueda R
Gan To Kagaku Ryoho; 2002 Jan; 29(1):149-53. PubMed ID: 11816473
[TBL] [Abstract][Full Text] [Related]
7. [Detection of soluble interleukin-2 receptor in the serum of patients with non-Hodgkin's lymphoma].
Pérez Encinas M; Bello JL; Bendaña A; Rabuñal MJ; González S; Abuín I; Noya M; Cadarso C
Med Clin (Barc); 1998 Jul; 111(5):161-7. PubMed ID: 9732831
[TBL] [Abstract][Full Text] [Related]
8. Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin's lymphoma.
Bien E; Balcerska A
Scand J Immunol; 2009 Nov; 70(5):490-500. PubMed ID: 19874554
[TBL] [Abstract][Full Text] [Related]
9. Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma.
Broyde A; Boycov O; Strenov Y; Okon E; Shpilberg O; Bairey O
Am J Hematol; 2009 Jun; 84(6):338-43. PubMed ID: 19384938
[TBL] [Abstract][Full Text] [Related]
10. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease.
Querellou S; Valette F; Bodet-Milin C; Oudoux A; Carlier T; Harousseau JL; Chatal JF; Couturier O
Ann Hematol; 2006 Nov; 85(11):759-67. PubMed ID: 16871391
[TBL] [Abstract][Full Text] [Related]
11. [Validity of the International Prognostic Index in non-Hodgkin's lymphomas of varying grades of malignancy].
Bettini R; Caronni F; Maino C; Marzetta K; Sala D; Saccà V; Gorini M
Recenti Prog Med; 2003 Nov; 94(11):494-500. PubMed ID: 14679917
[TBL] [Abstract][Full Text] [Related]
12. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
13. [Nucleolar organizer as a marker of malignancy grade and prognosis of non-Hodgkin's malignant lymphoma].
Raĭkhlin NT; Bukaeva IA; Probatova NA; Smirnova EA; Tupitsyn NN; Sholokhova EN
Arkh Patol; 1996; 58(4):22-8. PubMed ID: 8967858
[TBL] [Abstract][Full Text] [Related]
14. Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkin's lymphoma: an exploratory study.
Kube D; Hua TD; von Bonin F; Schoof N; Zeynalova S; Klöss M; Gocht D; Potthoff B; Tzvetkov M; Brockmöller J; Löffler M; Pfreundschuh M; Trümper L
Clin Cancer Res; 2008 Jun; 14(12):3777-84. PubMed ID: 18559596
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis of lymphoproliferative disorders: experience of a single institution in the long-term follow-up of discordant cases.
Sadek I; Greer W; Foyle A
Clin Invest Med; 2000 Dec; 23(6):366-75. PubMed ID: 11152404
[TBL] [Abstract][Full Text] [Related]
16. Profiles and prognostic values of serum LDH isoenzymes in patients with haematopoietic malignancies.
Bouafia F; Drai J; Bienvenu J; Thieblemont C; Espinouse D; Salles G; Coiffier B
Bull Cancer; 2004; 91(7-8):E229-40. PubMed ID: 15381461
[TBL] [Abstract][Full Text] [Related]
17. [The importance of the radioimmunological determination of tumor markers in the diagnosis of malignant lymphomas].
Purizhanskiĭ II; Pavlichuk SN; Toritsina LK
Med Radiol (Mosk); 1989 Nov; 34(11):48-51. PubMed ID: 2685505
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of elevated levels of serum soluble interleukin-2 receptor alpha (sIL-2Rα) in patients with non-Hodgkin's lymphoma.
Jo SA; Hwang SH; Chang CL; Kim SY; Shin HJ; Chung JS; Sol MY; Lee EY
Korean J Lab Med; 2010 Dec; 30(6):600-5. PubMed ID: 21157146
[TBL] [Abstract][Full Text] [Related]
19. [Significance of soluble interleukin-2 receptor alpha chain in the management of patients with malignant lymphoma: a multi-center study].
Ohno H; Ishikawa T; Kitajima H; Nomura S; Suzuki T; Konishi H; Ohno Y; Onishi R; Konaka Y; Arima N; Doi S; Nasu K; Takahashi T; Tsudo M; Fukuhara S; Uchiyama T
Rinsho Ketsueki; 2002 Mar; 43(3):170-5. PubMed ID: 11979748
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of Ki-67 antigen expression in non-Hodgkin's lymphomas.
Szczuraszek K; Mazur G; Jeleń M; Dziegiel P; Surowiak P; Zabel M
Anticancer Res; 2008; 28(2A):1113-8. PubMed ID: 18507062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
